María Rios

Prospective Multicentric Randomized Phase III Study of Imatinib in Patients With Advanced Gastrointestinal Stromal Tumors Comparing Interruption Versus Continuation of Treatment Beyond 1 Year: The French Sarcoma Group

Jean‐Yves Blay, Axel Le Cesne, Isabelle Ray‐Coquard et al. · Journal of Clinical Oncology · 2007 · 391 citations

Medicine, Oncology, Pharmacotherapy +11

Improved survival using specialized multidisciplinary board in sarcoma patients

Jean‐Yves Blay, Pauline Soibinet, Nicolas Penel et al. · Annals of Oncology · 2017 · 362 citations · Full text

Medicine, Oncology, Surgery +10

6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial

X. Pivot, Gilles Romieu, Marc Debled et al. · The Lancet Oncology · 2013 · 338 citations

Medicine, Oncology, Breast Oncology +14

Surgery in reference centers improves survival of sarcoma patients: a nationwide study

Jean‐Yves Blay, Charles Honoré, Eberhard Stoeckle et al. · Annals of Oncology · 2019 · 332 citations · Full text

Medicine, Oncology, Surgery +14

Discontinuation of imatinib in patients with advanced gastrointestinal stromal tumours after 3 years of treatment: an open-label multicentre randomised phase 3 trial

Axel Le Cesne, Isabelle Ray‐Coquard, Binh Bui et al. · The Lancet Oncology · 2010 · 295 citations

Medicine, Oncology, Pharmacotherapy +8